Results 41 to 50 of about 622,112 (341)

Comprehensive assessment of miniature CRISPR-Cas12f nucleases for gene disruption

open access: yesNature Communications, 2022
CRISPR-Cas12f nucleases can be effectively packaged into AAVs for gene therapy, but a systematic evaluation of editing outcomes is lacking. Here the authors perform a comprehensive assessment of 4 Cas12f proteins and compare to Cas9 and two Cas12a ...
Changchang Xin   +6 more
doaj   +1 more source

Large-Scale CRISPR Screen of LDLR Pathogenic Variants

open access: yesResearch, 2023
Familial hypercholesterolemia (FH) is a frequently occurring genetic disorder that is linked to early-onset cardiovascular disease. If left untreated, patients with this condition can develop severe cardiovascular complications.
Mengjing Li   +9 more
doaj   +1 more source

Genome Editing with Crispr-Cas9 Systems: Basic Research and Clinical Applications [PDF]

open access: yes, 2017
BACKGROUND: Recently established genome editing technologies will open new avenues for biological research and development. Human genome editing is a powerful tool which offers great scientific and therapeutic potential.CONTENT: Genome editing using the ...
Dewi, N. M. (Nurrani)   +2 more
core   +4 more sources

CAS9 is a genome mutator by directly disrupting DNA-PK dependent DNA repair pathway. [PDF]

open access: yes, 2020
With its high efficiency for site-specific genome editing and easy manipulation, the clustered regularly interspaced short palindromic repeats (CRISPR)/ CRISPR associated protein 9 (CAS9) system has become the most widely used gene editing technology in ...
Chen, Qu   +6 more
core  

Live pigs produced from genome edited zygotes [PDF]

open access: yes, 2013
Transcription activator-like effector nuclease (TALEN) and zinc finger nuclease (ZFN) genome editing technology enables site directed engineering of the genome.
AJ Clark   +13 more
core   +1 more source

Differentially activated B cells develop regulatory phenotype and show varying immunosuppressive features: a comparative study

open access: yesFrontiers in Immunology, 2023
Regulatory B lymphocytes (Bregs) are B cells with well-pronounced immunosuppressive properties, allowing them to suppress the activity of effector cells.
Elina A. Zheremyan   +11 more
doaj   +1 more source

Cell Surface-Expressed GPI-Anchored Peptides from the CHR Domain of gp41 Are Potent Inhibitors of HIV-1 Fusion

open access: yesProceedings, 2020
Current antiretroviral therapy efficiently suppresses viral replication but cannot eliminate latent HIV reservoirs. Moreover, the associated high costs, side effects, and drug resistance have stimulated a need for the development of alternative methods ...
Aleksandra Maslennikova   +3 more
doaj   +1 more source

The anti‐CRISPR protein AcrIE8.1 inhibits the type I‐E CRISPR‐Cas system by directly binding to the Cascade subunit Cas11

open access: yesFEBS Letters, EarlyView.
In this study, we present the structure of AcrIE8.1, a previously uncharacterized anti‐CRISPR protein that inhibits the type I‐E CRISPR‐Cas system. Through a combination of structural and biochemical analyses, we demonstrate that AcrIE8.1 directly binds to the Cas11 subunit of the Cascade complex to inhibit the CRISPR‐Cas system.
Young Woo Kang, Hyun Ho Park
wiley   +1 more source

PtWAVE: a high-sensitive deconvolution software of sequencing trace for the detection of large indels in genome editing

open access: yesBMC Bioinformatics
Background Tracking of Insertions and DEletions (TIDE) analysis, which computationally deconvolves capillary sequencing data derived from the DNA of bulk or clonal cell populations to estimate the efficiency of targeted mutagenesis by programmable ...
Kazuki Nakamae   +5 more
doaj   +1 more source

Methodological landscape in the field of integration site identification of retroviruses and retroviral vectors

open access: yesFrontiers in Bioengineering and Biotechnology
Detailed mapping of viral vector integration sites, including retroviral and particularly lentiviral vectors, is critical for assessing their safety in preclinical and clinical studies.
Konstantin Kochergin-Nikitsky   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy